Acalabrutinib A144-10MG

产品介绍

Acalabrutinib is a highly selective, irreversible inhibitor of Bruton's tyrosine kinase (BTK), and is being considered for use in the treatment of relapsed chronic lymphoid leukemia. Mutations in BTK result in a variety of B-cell related malignancies, as it upsets the B cell's signalling pathways.